Answers are grounded in this paper and cite their sources.
Pulmonary hypertension is a recognised complication of fibrotic interstitial lung disease, but hypersensitivity pneumonitis has never had a dedicated synthesis. Estimates come from single centres and from mixed interstitial lung disease series in which hypersensitivity pneumonitis is a small minority, and how much of the variation between reports reflects the detection method rather than real differences in disease burden is unknown. PubMed and Europe PMC were searched from inception to 24 August 2026, with reference list and forward citation searching. Observational studies reporting pulmonary hypertension in at least ten adults with hypersensitivity pneumonitis, or its association with mortality, were eligible. Two reviewers screened, extracted and appraised all reports independently. Cohorts were graded into three tiers by quality of ascertainment. Prevalence was pooled by random effects on the logit scale, restricted to tier 1 cohorts applying an explicit definition to every patient. Risk of bias used the Joanna Briggs Institute prevalence checklist and the Quality In Prognosis Studies tool. Of 108 screened records, 19 reports representing 18 distinct cohorts were included. The pooled prevalence across 12 tier 1 cohorts (1607 patients, 720 with pulmonary hypertension) was 36.1% (95% CI 27.7 to 45.5) (I² = 87.6%, 95% prediction interval 11.9 to 70.3%). Ascertainment method explained more of this variation than any other factor: 52.1% (95% CI 46.3 to 57.9) by right heart catheterisation against 26.9% (95% CI 21.2 to 33.5) by echocardiography ( p < 0.001). The estimate remained between 29.4 and 45.6% across ten sensitivity analyses and between 33.9 and 38.7% on leave one out testing. Fibrotic disease more than doubled the risk (risk ratio 2.21 (95% CI 1.16 to 4.22), 5 cohorts, I² = 71.4%). Pulmonary hypertension was associated with mortality in an exploratory pooled analysis of three estimates (2.06 (95% CI 1.33 to 3.18), I² = 0.0%), supported by 6 further cohorts. Roughly one in three patients with hypersensitivity pneumonitis assessed in specialist practice has pulmonary hypertension, rising to about one in two when the diagnosis is made by right heart catheterisation. That figure exceeds the pooled catheterisation estimate for interstitial lung disease overall, which argues against treating hypersensitivity pneumonitis as low risk for pulmonary vascular disease. Echocardiography with conventional thresholds substantially underestimates the burden.
No takes yet. Share an insight, caveat, or question.
Gohri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: